Skip to product information
1 of 1

MULTI SCIENCES

Human PRLR ELISA Kit For Protein Quantification

Human PRLR ELISA Kit For Protein Quantification

SKU:EK1180

Regular price Send Inquiry
Regular price Sale price Send Inquiry
Sale Sold out
View full details

Product Details

Human PRLR ELISA Kit For Protein Quantification

Brand

MultiSciences

Cat Num

70-EK1180

Product Name

Human PRLR ELISA Kit

Customs Name

Human PRLR ELISA Kit

Application

ELISA

Reactivity

Human

Assay Type

Sandwich ELISA

Suitable Sample Type

serum, plasma, cell culture supernates

Format

96-well strip plate

Storage

4℃ (unopened)standard stored at -20℃, others stored at 4℃ (opened)

Shipping Condition

4℃

Sample Volume

50 μl

Sensitivity

1.41 pg/ml

Standard Curve Range

15.63 - 1000 pg/ml

Spike Recovery Range

82 % - 122 %

Mean Spike Recovery

1.02

CV of Intra plate

2.0 % - 2.8 %

CV of Inter plate

1.6 % - 3.4 %

Components

96-well polystyrene microplate coated with a monoclonal antibody against PRLR
Human PRLR Standard, lyophilized
PRLR Detect Antibody
Standard Diluent
Assay Buffer (10×)
Substrate (TMB)
Stop Solution
Washing Buffer (20×)
Plate Covers

Describtion

This assay employs the quantitative sandwich enzyme immunoassay technique for the quantitative detection of human PRLR. The Human PRLR ELISA is for research use only. Not for diagnostic or therapeutic procedures.
The prolactin receptor (PRLR), a cytokine receptor— encoded by a gene on chromosome 5p13-14— interacts with prolactin as a transmembrane receptor. Thus it contains an extracellular region that binds prolactin, a transmembrane region, and a cytoplasmatic region. PRLR is widely expressed in breast, placenta, kidney, liver and pancreas and also activated by growth hormone (GH) and human placental lactogen (hPL) in addition to prolactin. It has been well documented that abnormity of PRLR is closely related to the pathogenesis, progression and prognosis of cancers including breast cancer. Specific binding to PRLR can stimulate the breast cancer cells to grow and certain antagonists which bind but do not dimerize PRLR can inhibit the growth of breast cancer cells. Several isoforms have been described, and the soluble form are unable to transduce prolactin signaling.